Ian Hagemann
Program Director · Washington University/B-JH/SLCH Consortium
Credentials: · · · · · · · ·
History
- 2013–2015
Clinical Informatics
Research
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells
Nature · 2011 · 1,116 citations
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Nature Medicine · 2014 · 841 citations
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis
Systematic review or meta-analysis · Gynecologic Oncology · 2012 · 545 citations
26 papers
23 papers · 3 as a fellow
23 papers
16 papers
15 papers
12 papers
12 papers · 1 as a fellow
11 papers
Grants
- 2023–2028
Route 66 Endometrial Cancer SPORE
National Cancer Institute · P50
Project lead · $582.7K · Washington University
Clinical trials
- 2026–2035
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
Sub-investigator · Not yet recruiting · Phase 1
Washington University School of Medicine
- 2025–2035
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Sub-investigator · Recruiting · Phase 1
Washington University School of Medicine
- 2024–2029
Uterine Preservation Via Lifestyle Transformation
Sub-investigator · Recruiting · Phase 2
Washington University School of Medicine
- 2024–2027
Sub-investigator · Recruiting · Phase 2
Washington University School of Medicine